KEGG   DRUG: DurvalumabHelp
Entry
D10808                      Drug                                   

Name
Durvalumab (USAN/INN);
Durvalumab (genetical recombination) (JAN);
Imfinzi (TN)
Product
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS RYWMSWVRQA PGKGLEWVAN IKQDGSEKYY
VDSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAREG GWFGELAFDY WGQGTLVTVS
SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSCDKTHTC PPCPAPEFEG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPASIEKTI SKAKGQPREP QVYTLPPSRE
EMTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
EIVLTQSPGT LSLSPGERAT LSCRASQRVS SSYLAWYQQK PGQAPRLLIY DASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSLPWTFG QGTKVEIKRT VAAPSVFIFP
PSDEQLKSGT ASVVCLLNNF YPREAKVQWK VDNALQSGNS QESVTEQDSK DSTYSLSSTL
TLSKADYEKH KVYACEVTHQ GLSSPVTKSF NRGEC
(dimer; disulfide bridges: H22-H96, H148-H204, H224-L215, H230-H'230, H233-H'233, H265-H325, H371-H429, H'22-H'96, H'148-H'204, H'224-L'-225, H'265-H'325, H'371-H'429, L23-L89, L135-L195, L'23-L'89, L'135-L'195)
  Type
Peptide
Remark
Therapeutic category: 4291
ATC code: L01XC28
Product: D10808<JP/US>
Efficacy
Antineoplastic, Anti-PD-L1 antibody
  Disease
Urothelial carcinoma [DS:H00022]
Non-small cell lung cancer [DS:H00014]
Comment
Monoclonal antibody
Target
PDL1 (CD274) [HSA:29126] [KO:K06745]
  Pathway
hsa04514  Cell adhesion molecules (CAMs)
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC28 Durvalumab
      D10808  Durvalumab (USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10808  Durvalumab (USAN/INN); Durvalumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDL1 (CD274)
     D10808  Durvalumab (USAN/INN) <JP/US>
Antineoplastics [br08340.html]
 D10808
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10808
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10808
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10808
Pharmacogenomic biomarkers [br08341.html]
 Companion diagnostics
  D10808
BRITE hierarchy
Other DBs
CAS: 1428935-60-7
PubChem: 319075068
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system